D-Index & Metrics Best Publications
Microbiology
France
2023

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Microbiology D-index 72 Citations 19,918 341 World Ranking 1063 National Ranking 61
Medicine D-index 76 Citations 23,568 451 World Ranking 13845 National Ranking 419

Research.com Recognitions

Awards & Achievements

2023 - Research.com Microbiology in France Leader Award

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Disease
  • Cancer

His primary scientific interests are in Internal medicine, Gastroenterology, Immunology, Surgery and Prospective cohort study. His Gastroenterology research is multidisciplinary, incorporating elements of Fibrosis, Ribavirin and Liver biopsy. His Immunology study frequently draws connections to adjacent fields such as Vasculitis.

His Surgery research incorporates themes from Crohn's disease, Anesthesia, Incidence and Cohort. The concepts of his Viral disease study are interwoven with issues in Viral shedding and Asymptomatic. His work on Orthomyxoviridae as part of general Influenza A virus study is frequently connected to Bayes' theorem, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.

His most cited work include:

  • Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies (835 citations)
  • Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies (835 citations)
  • Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study (785 citations)

What are the main themes of his work throughout his whole career to date?

Fabrice Carrat mostly deals with Internal medicine, Immunology, Gastroenterology, Virology and Cohort. His research integrates issues of Ribavirin and Hepatitis C virus in his study of Internal medicine. Immunology is often connected to Confidence interval in his work.

As part of one scientific family, Fabrice Carrat deals mainly with the area of Gastroenterology, narrowing it down to issues related to the Inflammatory bowel disease, and often Crohn's disease. Fabrice Carrat interconnects Young adult, Pandemic and Epidemiology in the investigation of issues within Virology. His studies deal with areas such as Cancer and Cohort study as well as Cohort.

He most often published in these fields:

  • Internal medicine (43.67%)
  • Immunology (29.41%)
  • Gastroenterology (24.43%)

What were the highlights of his more recent work (between 2016-2021)?

  • Internal medicine (43.67%)
  • Gastroenterology (24.43%)
  • Cohort (20.14%)

In recent papers he was focusing on the following fields of study:

Fabrice Carrat spends much of his time researching Internal medicine, Gastroenterology, Cohort, Retrospective cohort study and Cohort study. Internal medicine and Hepatitis C virus are frequently intertwined in his study. His Gastroenterology research includes elements of Hepatocellular carcinoma, Liver transplantation, Case-control study and Hepatitis B.

His work in Cohort addresses issues such as Epidemiology, which are connected to fields such as Genetic diversity and Public health. Fabrice Carrat has researched Retrospective cohort study in several fields, including Odds ratio, Pregnancy, University hospital, Treatment outcome and Prospective cohort study. His Cohort study study combines topics in areas such as Proportional hazards model and Incidence.

Between 2016 and 2021, his most popular works were:

  • Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. (202 citations)
  • Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (179 citations)
  • Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. (175 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Disease

His primary areas of investigation include Internal medicine, Gastroenterology, Retrospective cohort study, Prospective cohort study and Erdheim–Chester disease. His Internal medicine study often links to related topics such as Immunology. His biological study spans a wide range of topics, including Large cohort, Overall survival and Systemic vasculitis.

His Gastroenterology study combines topics from a wide range of disciplines, such as Regimen, Vasculitis, Case-control study and Hepatitis C virus. His studies in Retrospective cohort study integrate themes in fields like Obstetrics, Treatment outcome, University hospital and Severe complication. His Prospective cohort study research is multidisciplinary, incorporating perspectives in Human metapneumovirus, Coronavirus and Respiratory virus, Respiratory system.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies

Fabrice Carrat;Fabrice Carrat;Elisabeta Vergu;Elisabeta Vergu;Elisabeta Vergu;Neil M. Ferguson;Magali Lemaitre;Magali Lemaitre.
American Journal of Epidemiology (2008)

1250 Citations

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

Laurent Beaugerie;Nicole Brousse;Anne Marie Bouvier;Jean Frédéric Colombel.
The Lancet (2009)

1105 Citations

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Fabrice Carrat;Firouzé Bani-Sadr;Stanislas Pol;Eric Rosenthal.
JAMA (2004)

1039 Citations

Influenza vaccine: the challenge of antigenic drift.

Fabrice Carrat;Antoine Flahault;Antoine Flahault.
Vaccine (2007)

815 Citations

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.

David Saadoun;Michelle Rosenzwajg;Florence Joly;Adrien Six.
The New England Journal of Medicine (2011)

765 Citations

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890

Christophe Hézode;Hélène Fontaine;Céline Dorival;Dominique Larrey.
Journal of Hepatology (2013)

540 Citations

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease

Laurent Peyrin–Biroulet;Kiarash Khosrotehrani;Fabrice Carrat;Anne–Marie Bouvier.
Gastroenterology (2011)

511 Citations

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.

Christophe Corpechot;Fabrice Carrat;Abbas Bahr;Yves Chrétien.
Gastroenterology (2005)

448 Citations

A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data.

S. Cauchemez;F. Carrat;C. Viboud;C. Viboud;A. J. Valleron.
Statistics in Medicine (2004)

436 Citations

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

Fabrice Carrat;Hélène Fontaine;Céline Dorival;Mélanie Simony.
The Lancet (2019)

376 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Fabrice Carrat

Fabien Zoulim

Fabien Zoulim

Inserm

Publications: 80

Patrice Cacoub

Patrice Cacoub

Sorbonne University

Publications: 70

Laurent Peyrin-Biroulet

Laurent Peyrin-Biroulet

University of Lorraine

Publications: 68

Keith D. Lindor

Keith D. Lindor

Arizona State University

Publications: 65

Cécile Viboud

Cécile Viboud

National Institutes of Health

Publications: 64

Jean-Frederic Colombel

Jean-Frederic Colombel

Icahn School of Medicine at Mount Sinai

Publications: 64

Benjamin J. Cowling

Benjamin J. Cowling

University of Hong Kong

Publications: 64

Stanislas Pol

Stanislas Pol

Université Paris Cité

Publications: 63

Vincent Soriano

Vincent Soriano

Hospital Universitario La Paz

Publications: 62

Gerardo Chowell

Gerardo Chowell

Georgia State University

Publications: 58

Lone Simonsen

Lone Simonsen

Roskilde University

Publications: 57

Thierry Poynard

Thierry Poynard

Université Paris Cité

Publications: 54

Gideon M. Hirschfield

Gideon M. Hirschfield

University Health Network

Publications: 52

Mark S. Sulkowski

Mark S. Sulkowski

Johns Hopkins University School of Medicine

Publications: 47

Bettina E. Hansen

Bettina E. Hansen

University Health Network

Publications: 46

David Klatzmann

David Klatzmann

Sorbonne University

Publications: 44

Trending Scientists

William T. Ziemba

William T. Ziemba

University of British Columbia

Tomoko Ohta

Tomoko Ohta

University of Tokyo

Feng Huang

Feng Huang

Sun Yat-sen University

Malik Maaza

Malik Maaza

University of South Africa

Roger J. Merry

Roger J. Merry

Aberystwyth University

Lloyd W. Ruddock

Lloyd W. Ruddock

University of Oulu

Stefan Heller

Stefan Heller

Stanford University

Mustafa B. A. Djamgoz

Mustafa B. A. Djamgoz

Imperial College London

Thomas F. Smith

Thomas F. Smith

Mayo Clinic

Howard W. Mielke

Howard W. Mielke

Tulane University

Peter P. Nawroth

Peter P. Nawroth

Heidelberg University

Mauro Delorenzi

Mauro Delorenzi

Swiss Institute of Bioinformatics

Paul Khairy

Paul Khairy

Montreal Heart Institute

Andrew J. Saykin

Andrew J. Saykin

Indiana University

Amber Peterman

Amber Peterman

University of North Carolina at Chapel Hill

Harold Wolman

Harold Wolman

George Washington University

Something went wrong. Please try again later.